Results of 2023 Annual General Meeting

Ergomed plc

22 June 2023

 

Results of 2023 Annual General Meeting

Guildford, 22 June 2023: Ergomed plc (AIM: ERGO) ("Ergomed" or the "Company"), a company focused on providing specialised services to the pharmaceutical industry, announces the results of voting on the resolutions put to shareholders at its Annual General Meeting held earlier today.  All resolutions were duly passed.

Details of the voting by way of a poll at the AGM in respect of each resolution are shown in the table below:

Resolution number	Resolution	Votes for	Votes against	Abstentions
1	Accounts	39,697,194	912,240	81,986
2	Reappoint auditor	40,736,227	1,255	80
3	Reappoint Anne Whitaker	40,269,559	457,733	337
4	Reappoint Jonathan Curtain	40,607,611	129,614	337
5	Reappoint Llew Keltner	39,853,733	827,308	446
6	Allot securities	38,791,006	1,946,219	337
7	Pre-emption rights	38,049,052	2,498,173	190,337
8	Pre-emption rights (acquisition)	38,061,085	2,676,140	337

The full text of all resolutions can be found in the Notice of Annual General Meeting on the Company's website www.ergomedplc.com.

ENDS

Enquiries:

Ergomed plc	Tel: [phone]
Miroslav Reljanović (Executive Chairman)
Jonathan Curtain (Chief Financial Officer) Keith Byrne (Senior Vice President, Capital Markets and Strategy)
Numis Securities Limited (Nominated Adviser and Joint Broker)	Tel: [phone]
Freddie Barnfield / Euan Brown / Jack McLaren
Peel Hunt Securities Limited (Joint Broker) James Steel / Dr Christopher Golden	Tel: [phone]
Consilium Strategic Communications -for UK enquiries	Tel: [phone]
Chris Gardner / Matthew Neal	[e-mail]

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO) and mission-critical regulatory compliance and consulting services under the ADAMAS brand. For further information, visit: http://ergomedplc.com.

 

END